News, stories and opinions for the business innovators of the world.

Atmo Biosciences wins $620k grant to advance commercialization of ingestible gas-sensing capsule to diagnose gut disorders

Suraya SalehMarketing Communications Manager

Atmo Biosciences, a digital health business which provides objective real-time insights into gut health and microbiome function, has been awarded a $620,000 Australian Government grant through the BioMedTech Horizons (BMTH) program.

Delivered by MTPConnect and funded by the Medical Research Future Fund, the BMTH program supports the commercialization of innovative collaborative health technologies. Atmo was one of 21 successful companies selected by the program, which was announced by the Hon. Greg Hunt, Minister for Health, on July 19.

Atmo, one of a portfolio of businesses incubated by Planet Innovation, is addressing the unmet clinical need to interrogate and monitor the function of the gut microbiota. This will allow better diagnosis and development of personalized therapies for gastrointestinal disorders, resulting in earlier and more successful relief of symptoms, and reduced healthcare costs.

Atmo’s platform is underpinned by the Atmo Gas Capsule, a world-first ingestible gas-sensing capsule that senses clinically important gaseous biomarkers produced by the microbiome in the gastrointestinal system. This data is wirelessly transmitted to the cloud for aggregation and analysis.

Atmo Biosciences CEO Mal Hebblewhite said the BMTH funding would be used to demonstrate the commercial application of the Atmo platform in identifying Irritable Bowel Syndrome (IBS) subtypes and diagnosing Small Intestinal Bacterial Overgrowth (SIBO). This includes developing machine learning algorithms to determine the constituents of complex gas mixtures relevant to IBS and SIBO, and conducting a clinical trial to validate the algorithm against current diagnostic standards.

“IBS affects up to 1 in 5 adults, but there is currently no definitive test or biomarker; diagnosis, treatment and management is challenging because it is based almost entirely on symptoms,” Mal said.

“I’d like to thank the Australian Government and MTPConnect for this support, which will help us improve the way gastrointestinal disorders are diagnosed and treated, thereby making a huge difference to the quality of life of millions of IBS and SIBO sufferers worldwide.”

Visit the Atmo Biosciences website.

SHARE THIS ARTICLE:
Suraya Saleh Marketing Communications Manager
Suraya Saleh

Suraya is the Marketing Communications Manager at Planet Innovation. A former journalist, Suraya is passionate about telling engaging stories for companies that have a positive impact on the world.

Suraya Saleh
Topics.

Sign up for the Perspectives newsletter:

A roundup of the latest news and opinions from PI.

Related Articles.

PI launches Atmo Biosciences to commercialize ingestible gas-sensing capsule for gut health

News

Atmo Biosciences, a Planet Innovation early stage venture, has signed a licensing deal with RMIT University to secure the exclusive worldwide rights to a ground-breaking ingestible gas-sensing capsule.

Atmo Biosciences and Seed Health announce research partnership to evaluate impact of probiotics on gut microbiome

News

Seed Health, a US-based microbial sciences company, and Atmo Biosciences, a Planet Innovation early stage venture, have announced a partnership to use Atmo’s ingestible gas-sensing capsule to study the impact of probiotics on the gut microbiome.

Atmo Biosciences raises $2.5m in seed financing

News

Atmo Biosciences, a digital health business that provides objective real-time insights into gut health and microbiome function, has raised a further A$2.5 million in an oversubscribed funding round, supplementing an initial seed raise in March 2019.

Tackling the global health threat of antibiotic resistance through Lumos Diagnostics and the FebriDx test

Diagnostics

November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.

News

PI launches Atmo Biosciences to commercialize ingestible gas-sensing capsule for gut health

Atmo Biosciences, a Planet Innovation early stage venture, has signed a licensing deal with RMIT University to secure the exclusive worldwide rights to a ground-breaking ingestible gas-sensing capsule.